Immix Biopharma Inc
NASDAQ:IMMX

Watchlist Manager
Immix Biopharma Inc Logo
Immix Biopharma Inc
NASDAQ:IMMX
Watchlist
Price: 5.1 USD -6.08% Market Closed
Market Cap: 268.7m USD

Immix Biopharma Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Immix Biopharma Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Immix Biopharma Inc
NASDAQ:IMMX
Free Cash Flow
-$15.8m
CAGR 3-Years
-115%
CAGR 5-Years
-82%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

Immix Biopharma Inc
Glance View

Market Cap
268.7m USD
Industry
Biotechnology

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the development of therapies for patients with cancer and inflammatory diseases. The company is developing a class of tissue-specific therapeutics (TSTx) in oncology and inflammation. The Company’s lead asset, IMX-110, is is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology, which is delivered into the TME. IMX-110, is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor.

IMMX Intrinsic Value
1.65 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Immix Biopharma Inc's Free Cash Flow?
Free Cash Flow
-15.8m USD

Based on the financial report for Dec 31, 2024, Immix Biopharma Inc's Free Cash Flow amounts to -15.8m USD.

What is Immix Biopharma Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-82%

Over the last year, the Free Cash Flow growth was -38%. The average annual Free Cash Flow growth rates for Immix Biopharma Inc have been -115% over the past three years , -82% over the past five years .

Back to Top